The impact of the COVID-19 pandemic on the financial sector in medicine: features of centralized state procurement of drugs and medical devices in Ukraine for the period 2018-2021
ABSTRACT. Coronavirus disease (COVID-19) has deeply impacted the global health care system, and the redistribution of funding for medical care violated the prevention and treatment of chronic non-communicable diseases, including hypertension, tuberculosis, and HIV. In 2020, centralized state procurement of medicines in Ukraine was for the first time conducted via the online platform Prozorro. Of the 483 items planned to be purchased, 375 items (78 %) were successfully contracted. In the current 2021, tenders were announced for the purchase of 555 of 562 items. In most fields of medicine, the drugs to be purchased are 100 % covered by tenders. The lowest percentage of coverage is observed for pulmonary arterial hypertension (66.67 %).
In today’s complex environment, not only COVID-19 should be actively combated, but other diseases should be also kept in mind when carefully planning the funding of various fields of medicine through the analysis of data from previous years. The money saved can be used to eliminate the consequences of the COVID-19 pandemic, and to purchase the necessary medicines. The creation of a single database of drug residues in medical institutions (chatbot in the Telegram messenger) can be called a positive innovation. Control of drug residues and their adequate redistribution makes it possible to rationally use this resource without spending money on unnecessary purchases.
In general, despite the medical and financial impact of COVID-19, Ukraine’s healthcare system continues to withstand pressure and change for the better. Further improvement of the system of centralized procurement of medicines will be able to overcome the problem of lack of necessary drugs.
Sobral M.F.F., Duarte G.B., da Penha Sobral A.I.G., et al. Association between climate variables and global transmission of SARS-CoV-2. Sci. Total Environ. 2020; 729:138997.
Narayan Y.U., Binod R., Kanti M.S., et al. A syndemic perspective on the management of non-communicable diseases amid the COVID-19 pandemic in low- and middle-income countries. Frontiers in Public Health. 2020; 8.
Heron M. Deaths: leading causes for 2017. National Vital Statistics Reports. 2019 June 24; vol. 68, N. 6.
Wu Z., McGoogan J. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. J. Am. Med. Assoc. 2020; 323: 1239-1242.
Ahmed J., Malik F., Bin Arif T. Availability of personal protective equipment (PPE) among US and Pakistani doctors in COVID-19 pandemic. Cureus. 2020; 12: е8550.
Suleiman A., Bsisu I., Guzu H. Preparedness of frontline doctors in Jordan healthcare facilities to COVID-19 outbreak. Int. J. Environ. Res. Publ. Health. 2020; 17: 3181.
Kaye A.D., Okeagu C.N., Pham A.D., et al. Economic impact of COVID-19 pandemic on healthcare facilities and systems: international perspectives. Best Pract. Res. Clin. Anaesthesiol. 2020.
White Paper: leading the conversation on noncommunicable diseases worldwide: an evidence-based review of key research and strategies to develop sustainable solutions. Upjoin: Kalamazoo, MI, USA, 2020.
Ahmed S.A.K.S., Ajisola M., Azeem K. Impact of the societal response to COVID-19 on access to healthcare for non-COVID-19 health issues in slum communities of Bangladesh, Kenya, Nigeria and Pakistan: results of pre-COVID and COVID-19 lockdown stakeholder engagements. BMJ Glob. Health. 2020; 5: е003042.
World Health Organization (WHO). Information note: COVID-19 and NCDs. 2020. Available at: https://www.who.int/docs/default-source/inaugural-who-partners-forum/covid-19-and-ncds---final---corr7.pdf?sfvrsn=9b65e287_1&download=true.
Negrini S., Grabljevec K., Boldrini P., et al. Up to 2.2 million people experiencing disability suffer collateral damage each day of COVID-19 lockdown in Europe. Eur. J. Phys. Rehabil. Med. 2020; 56: 361-365.
Caminiti C., Maglietta G., Meschi T., et al. Effects of the COVID-19 epidemic on hospital admissions for non-communicable diseases in a large Italian university-hospital: a descriptive case-series study. J. Clin. Med. 2021; 10: 880.
Jones D., Neal R.D., Duffy S.R.G., et al. Impact of the COVID-19 pandemic on the symptomatic diagnosis of cancer: the view from primary care. Lancet Oncol. 2020; 21: 748-750.
Mafham M.M., Spata E., Goldacre R., et al. COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England. Lancet. 2020; 396: 381-389.
Kansagra A.P., Goyal M.S., Hamilton S., Albers G.W. Collateral effect of COVID-19 on stroke evaluation in the United States. N. Engl. J. Med. 2020; 383 (4): 400-401.
Parikh K.D., Ramaiya N.H., Kikano E.G., et al. COVID-19 pandemic impact on decreased imaging utilization: a single institutional experience. Acad. Radiol. 2020; 27: 1204-1213.
Zhao J., Li H., Kung D., et al. Impact of the COVID-19 epidemic on stroke care and potential solutions. Stroke; J. Cereb. Circul. 2020; STROKEAHA120030225.
Mesnier J., Cottin Y., Coste P., et al. Hospital admissions for acute myocardial infarction before and after lockdown according to regional prevalence of COVID-19 and patient profile in France: a registry study. Lancet Public Health. 2020; 5: e536-ee42.
De Rosa S., Spaccarotella C., Basso C., et al. Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. Eur. Heart J. 2020; 41: 2083-2088.
Randau T.M., Jaenisch M., Haffer H. Collateral effect of COVID-19 on orthopedic and trauma surgery. PloS One. 2020; 15: 1-17.
Montemurro P., Heden P., Adams W. Effects of COVID-19 on plastic surgery practices and medi-spas in different countries. Aesthet. Surg. J. 2020; 40: NP453-NP456.
Martinez D., Sarria G., Wakefield D. COVID’s impact on radiation oncology: a Latin American survey study. Int. J. Radiat. Oncol. Biol. Phys. 2020; 108: 374-378.
This work is licensed under a Creative Commons Attribution 4.0 International License.